WO2007011232A3 - Lipid lowering agents for increasing bmd - Google Patents

Lipid lowering agents for increasing bmd Download PDF

Info

Publication number
WO2007011232A3
WO2007011232A3 PCT/NO2006/000263 NO2006000263W WO2007011232A3 WO 2007011232 A3 WO2007011232 A3 WO 2007011232A3 NO 2006000263 W NO2006000263 W NO 2006000263W WO 2007011232 A3 WO2007011232 A3 WO 2007011232A3
Authority
WO
WIPO (PCT)
Prior art keywords
bmd
lowering agents
lipid lowering
increasing
increasing bmd
Prior art date
Application number
PCT/NO2006/000263
Other languages
French (fr)
Other versions
WO2007011232A2 (en
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Rolf Berge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As, Rolf Berge filed Critical Thia Medica As
Publication of WO2007011232A2 publication Critical patent/WO2007011232A2/en
Publication of WO2007011232A3 publication Critical patent/WO2007011232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention comprises the use of a fibrate and/or the compound Wyeth 14,643 for preparation of a pharmaceutical composition for the prevention and/or treatment of conditions associated with low/decreased bone mineral density (BMD), and/or for increasing the BMD by decreasing the bone resorption.
PCT/NO2006/000263 2005-07-18 2006-07-10 Lipid lowering agents for increasing bmd WO2007011232A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20053517A NO20053517L (en) 2005-07-18 2005-07-18 Use of lipid-lowering agents
NO20053517 2005-07-18

Publications (2)

Publication Number Publication Date
WO2007011232A2 WO2007011232A2 (en) 2007-01-25
WO2007011232A3 true WO2007011232A3 (en) 2007-06-07

Family

ID=35295501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NO2006/000263 WO2007011232A2 (en) 2005-07-18 2006-07-10 Lipid lowering agents for increasing bmd

Country Status (2)

Country Link
NO (1) NO20053517L (en)
WO (1) WO2007011232A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2040694A2 (en) * 2006-07-14 2009-04-01 VIB vzw Use of ppar-alpha agonists to treat skeletal muscle wasting disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053003A1 (en) * 1999-10-19 2001-06-28 Univ Jw Goethe Frankfurt Main Treatment of immunologically induced skin disorders, skin aging or neuropathy, comprises using peroxisome-proliferator activated receptor, alpha, beta activators such as pirinixic acid
WO2001060355A1 (en) * 2000-02-15 2001-08-23 University Of Sheffield Modulation of bone formation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053003A1 (en) * 1999-10-19 2001-06-28 Univ Jw Goethe Frankfurt Main Treatment of immunologically induced skin disorders, skin aging or neuropathy, comprises using peroxisome-proliferator activated receptor, alpha, beta activators such as pirinixic acid
WO2001060355A1 (en) * 2000-02-15 2001-08-23 University Of Sheffield Modulation of bone formation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INZERILLO A M ET AL: "OSTEOPOROSIS AND DIABETES MELLITUS", REVIEWS IN ENDOCRINE AND METABOLIC DISORDERS, XX, XX, vol. 5, no. 3, 2004, pages 261 - 268, XP008070665 *
SHEA J E ET AL: "Alterations in skeletal and mineral metabolism following thermal injuries.", JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS SEP 2003, vol. 3, no. 3, September 2003 (2003-09-01), pages 214 - 222, XP008077102, ISSN: 1108-7161 *
SYVERSEN U ET AL: "THE PPAR-ALPHA AGONIST WYETH 14643 INCREASES BONE MINERAL DENSITY IN FEMALE RATS", JOURNAL OF BONE AND MINERAL RESEARCH, NEW YORK, NY, US, vol. 16, no. SUPPLEMENT 1, September 2001 (2001-09-01), pages S222,ABSTRACTF419, XP008070679, ISSN: 0884-0431 *

Also Published As

Publication number Publication date
NO20053517L (en) 2007-01-19
NO20053517D0 (en) 2005-07-18
WO2007011232A2 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2007120980A3 (en) 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
TW200722100A (en) A therapeutic agent for a β related disorders
WO2006073457A3 (en) Bioactive compounds and methods of uses thereof
WO2006089023A3 (en) Pharmaceutical compositions for treating or preventing bone conditions
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2006122186A3 (en) 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
HK1077515A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
HK1092467A1 (en) N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses n-
WO2005046603A3 (en) Pyridine compounds
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2006102610A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
PT2803366T (en) Compositions for treating or preventing oxalate-related disease
TW200621753A (en) Pyrimidinylimidazoles and methods of making and using the same
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
HK1155146A1 (en) Indene derivatives as pharmaceutical agents
WO2007028022A3 (en) Novel compounds as p2x7 modulators and uses thereof
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2006130726A3 (en) Use of ladostigil for the treatment of multiple sclerosis
WO2005112923A3 (en) 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
WO2007027519A3 (en) Compositions and methods for darkening keratinous fibers
WO2003066022A3 (en) Stable pharmaceutical composition useful for treating gastrointestinal disorders
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
WO2006023586A3 (en) Guanylhydrazone compounds, compositions, methods of making and using

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06769434

Country of ref document: EP

Kind code of ref document: A2